Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of DXC006 in multiple solid tumors and hematologic malignancies
CTR20262556Phase 2Active
- Sponsor
- Hangzhou DAC Biotech
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DXC-006 in small cell lung cancer (SCLC), glioma, multiple myeloma (MM), Non-small cell lung cancer adenocarcinoma (NSCLC), Pulmonary squamous cell carcinoma, sponsored by Hangzhou DAC Biotech. Started Jul 2026; status: active.
02
Drugs
DXC-006
03
Conditions
small cell lung cancer (SCLC)gliomamultiple myeloma (MM)Non-small cell lung cancer adenocarcinoma (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20262556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262556.